UID:
almafu_9960073756002883
Umfang:
1 online resource (xvii, 159 pages) :
,
illustrations (some color), portraits.
Ausgabe:
1st ed.
ISBN:
9780124072107
,
0124072100
,
9781299195738
,
1299195733
Serie:
Elsevier insights PAKs, RAC/CDC42 (p21)-activated kinases
Inhalt:
This book covers a variety of cutting-edge basic and clinical PAK research ranging from laboratory benches to hospital beds. The goal of this book is to inspire not only biomedical research scientists and university students, but also a variety of patients who suffer from PAK-dependent diseases and clinical doctors who try to cure or delay these PAK-dependent diseases. This book consists of 9 chapters which deal with different aspects of this kinase. These chapters are written by more than two dozen world-leading PAK experts. Each of these will provide updated biomedical information as well
Anmerkung:
Description based upon print version of record.
,
Front Cover; PAKs, RAC/CDC42 (p21)-activated Kinases; Copyright Page; Contents; List of Contributors; Introduction: Pushing the Boundary Toward Clinical Application: After 35 Years, PAK Research Comes of Age; Acknowledgments; References; 1 Functional Maturation of PAKs from Unicellular to Multicellular Organisms; 1.1 Introduction; 1.2 MIHCKs/PAKs and Myosin I in Unicellular Acanthamoeba and Multicellular Dictyostelium; 1.3 PAK Evolution Among Metazoans (Unicellular Versus Multicellular); 1.3.1 Choanoflagellates Versus Freshwater Sponges; 1.3.2 Soil Amoeba Versus Cellular Slime Mold
,
1.4 PIX in Fruit Fly Drosophila and Nematode C. elegans1.5 FYN/ETK-Dependent Activation of PAK1; 1.6 Evolution of Merlin, Nischarin, and LBK1 (PAK Inhibitors); 1.6.1 Merlin; 1.6.2 Nischarin; 1.6.3 LKB1; 1.7 Concluding Remarks; Acknowledgment; References; 2 Oncogenicity of PAKs and Their Substrates; 2.1 Introduction; 2.2 Loss of Contact Inhibition of Growth; 2.3 Serum-Independent Growth; 2.4 Anchorage-Independent Growth; 2.5 Tumor-Induced Angiogenesis; 2.6 Metastasis/Invasion; 2.7 PAK1/PAK4-Dependent Solid Tumors; 2.7.1 Pancreatic Cancer; 2.7.2 Colon/Gastric Cancer; 2.7.3 Breast Cancer
,
2.7.4 Cervical Cancer and Papillomas2.7.5 Prostate Cancer; 2.7.6 Neurofibromatosis; 2.7.7 Lung Cancer; 2.7.8 Human Malignant Mesothelioma (HMM); 2.7.9 Ovarian Cancer; 2.7.10 Thyroid Cancer; 2.7.11 Multiple Myeloma; 2.7.12 Gliomas; 2.7.13 Hepatocellular Carcinomas; 2.7.14 Melanoma; 2.8 Oncogenic Targets of PAKs; 2.8.1 PAK Substrates and Their Phosphorylation Sites; 2.8.2 RAF/MEK/ERK Pathways; 2.8.3 LIM Kinase/Cofilin Pathway; 2.8.4 β-Catenin; 2.8.5 Estrogen Receptor; 2.8.6 Integrin-Linked Kinase; 2.8.7 c-Jun N-Terminal Kinase; 2.8.8 Aurora-A; 2.8.9 BAD/Bcl-2 Pathway; 2.8.10 FOXO (FKHR)
,
2.8.11 Merlin2.9 Concluding Remarks; Acknowledgments; References; 3 Natural or Synthetic Therapeutics That Block PAKs; 3.1 Introduction; 3.1.1 The Dawn of PAK1-3 Inhibitor Development; 3.1.2 The DN Mutant of PAK1 (cDNA); 3.1.3 TAT/WR-PAK18 (Peptide); 3.2 Synthetic Chemical Therapeutics; 3.2.1 CEP-1347 and ST3009/ST3010; 3.2.2 Combination of Two Tyr Kinase Inhibitors; 3.2.3 PF3758309 (UnPAK309 or PanPAK309); 3.3 Natural PAK1 Blockers; 3.3.1 FK228; 3.3.2 Propolis; 3.3.3 Antimalarial Drugs; 3.3.4 Chinese (Sichuan) Peppercorn Extract; 3.3.5 Curcumin; 3.3.6 Emodin; 3.3.7 Berberin; 3.3.8 Ivermectin
,
3.3.9 Salidroside3.4 PAK1 Blockers = AMPK Activators; Acknowledgments; References; 4 PAK1-3 in Infectious Diseases; 4.1 Malaria Infection; 4.2 Enterobacterial Infection; 4.2.1 Helicobacter pylori; 4.2.2 E. coli (Hemorrhagic Strain); 4.3 Viral Infection; 4.3.1 AIDS (HIV); 4.3.2 Influenza Virus; 4.3.3 Human Papilloma Virus; Acknowledgments; References; 5 PAK1 in Brain Diseases or Disorders; 5.1 Introduction; 5.2 Tumorigenesis: NF, TSC, Retinoblastoma, and Gliomas; 5.2.1 Neurofibromatosis; 5.2.2 Tuberous Sclerosis; 5.2.3 Retinoblastoma; 5.2.4 Glioma; 5.3 Epilepsy; 5.4 Mental Retardation
,
5.5 Schizophrenia
,
English
Weitere Ausg.:
ISBN 9780323282529
Weitere Ausg.:
ISBN 0323282520
Weitere Ausg.:
ISBN 9780124071988
Weitere Ausg.:
ISBN 0124071988
Sprache:
Englisch
Bookmarklink
